A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial

[1]  T. Bisdas,et al.  1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty. , 2018, JACC. Cardiovascular interventions.

[2]  D. Scheinert,et al.  12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment. , 2018, JACC. Cardiovascular interventions.

[3]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[4]  P. Teirstein,et al.  Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial. , 2017, JACC. Cardiovascular interventions.

[5]  Thomas Zeller,et al.  Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up , 2017, CardioVascular and Interventional Radiology.

[6]  P. Faries,et al.  Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease , 2017, Circulation.

[7]  C. Paetzel,et al.  The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon. , 2017, JACC. Cardiovascular interventions.

[8]  D. Kroetz,et al.  Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review , 2017, Clinical Pharmacokinetics.

[9]  T. Zeller,et al.  Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease , 2016, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[10]  M. Dake,et al.  Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery , 2016, Circulation.

[11]  D. Scheinert,et al.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.

[12]  V. Aboyans,et al.  Epidemiology of peripheral artery disease. , 2015, Circulation research.

[13]  J. Massaro,et al.  Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. , 2015, Journal of the American College of Cardiology.

[14]  D. Scheinert,et al.  Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease , 2015, Circulation.

[15]  Nancy M Albert,et al.  Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[16]  John V. White,et al.  Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[17]  M. Dake,et al.  Nitinol Stents With Polymer-Free Paclitaxel Coating for Lesions in the Superficial Femoral and Popliteal Arteries Above the Knee: Twelve-Month Safety and Effectiveness Results From the Zilver PTX Single-Arm Clinical Study , 2011, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[18]  H. Yokoi,et al.  Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[19]  M. Dake,et al.  Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.

[20]  Thomas Zeller,et al.  First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. , 2011, Journal of vascular surgery.

[21]  M. Dake,et al.  Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries. , 2011, Journal of vascular and interventional radiology : JVIR.

[22]  Gregg W Stone,et al.  A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. , 2011, Journal of the American College of Cardiology.

[23]  R. Dayal,et al.  An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety. , 2010, Journal of vascular surgery.

[24]  L. Norgren,et al.  Inter-society consensus for the management of peripheral arterial disease. , 2007, International angiology : a journal of the International Union of Angiology.

[25]  D. Bloch,et al.  Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[26]  L. Norgren,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, Journal of vascular surgery.

[27]  Jean-Paul Beregi,et al.  Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial , 2006, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[28]  R. Rutherford,et al.  Recommended standards for reports dealing with lower extremity ischemia: revised version. , 1997, Journal of vascular surgery.